Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novartis

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.

Benzinga

Novartis' Investigational Drug Aces Two Pivotal Trials For Chronic Disease Impacting Tears, Saliva

Novartis AG (NYSE:NVS) on Monday released topline data from two Phase 3 trials, NEPTUNUS-1 and NEPTUNUS-2, evaluating ianalumab (VAY736) in adults with active Sjögren’s disease.

Benzinga

The Latest: US trade partners around the world react to Trump's new tariffs

U.S. trade partners are reacting to President Donald Trump’s executive order that would introduce new tariffs on many of them in seven days

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

First malaria treatment for babies is a major step to ending the disease in Africa - biochemist

The first malaria treatment for babies and very young children of 2 months up to 5 years was approved for use by Swiss agency for therapeutic products, Swissmedic, in early July 2025. Until now, babies and very young children have been treated with medicines formulated for older children.

The Conversation

Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED)

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title.

Benzinga

Hope for developing world as Swiss anti-malarial for newborns approved

IN FULL

The Independent UK

First anti-malaria drug for newborns approved

The newly approved medication is a lower-dose version of a tablet previously approved for other age groups

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

World’s first malaria treatment for newborn babies gets approval

Several African countries where malaria is widespread are expected to swiftly approve the new medicine following Swissmedic’s decision.

Euronews

Americans would suffer most if Trump imposes pharma tariffs, sector warns

Industry says levies would hit supply chains, making medicines potentially unaffordable for some US patients

The Guardian - UK

Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot

The Guardian - UK

Novartis posts better-than-expected sales driven by medicine demand

The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core operating income set to grow by low double-digits.

Euronews

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

MarketBeat

Pill that slashes risk of breast cancer recurring to be available on NHS

Ribociclib (known by the brand name Kisqali) targets specific proteins that contribute to cancer cell growth

The Independent UK

EU holds firm on pharma reform proposal despite industry pressure

The European Commission has no plans to withdraw or revise its proposed overhaul of EU pharmaceutical rules, despite mounting pressure from the pharmaceutical industry concerned about potential tariffs and the sector’s competitiveness.

Euronews

Get all your
news in one place.

100's of premium titles.
One news app.

Latin Times

Roche Says Will Invest $50 Bn In US, As Tariff War Uncertainty Swells

Trump's administration is blowing hot and cold on pharmaceutical products, which initially benefited from exemptions in the round of tariffs announced on April 2.

Fortune

Swiss drugmaker Roche leans into Trump tariff formula with $50bn promise to invest in U.S.

Roche promised that its investments in the U.S. means it will export more medicines than it imports in the U.S.

Latin Times

Novartis Plans $23 Billion US Buildout as Pharma Faces Pressure From Trump

Novartis plans a $23 billion U.S. expansion to boost drug production and counter potential import tariffs.

Fortune

Europe’s pharma titans confront von der Leyen as Trump plans ’major’ tariffs

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

Behind $2 million per dose gene therapy

How did a drug rooted in government seed money and spurred by grassroots fundraising end up with such a price tag?

The Independent UK

Aliens, sloths and silliness: Super Bowl ads offer laughs, celebs and surprises to win over viewers

Eugene Levy’s trademark eyebrows fly off for Little Caesars

MarketBeat

AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Benzinga

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.

Benzinga

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

Fortune

From biopharma to real estate to shipping, top CEOs insist AI is worth the hype

Stop being afraid of newfangled technology, and start letting your kids use it to help them with their homework, said panelists at Fortune Global Forum.

International Business Times

'Pure-play' Novartis Raises 2024 Financial Targets

A year after spinning off its generics business to become a "pure-player" developer of innovative medicines, Novartis registered a 15 percent increase in its core net profit to $4.1 billion during the July-September period, from the same quarter last year.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Parliament

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.